ESR1 and lymphedema: Tamoxifen treatment not only worsens lymphedema by inhibiting genomic action of ERα, but also blocks the membrane non-genomic activity of the receptor by inhibiting ERK phosphorylation, thus suppressing the protective effect of E2 when both treatments are administered together [4].